Home Tags Pharmaceutical Industry

Pharmaceutical Industry Related Content

diagnostic medicine

Artificial Intelligence in diagnostic medicine – a tool to replace clinicians?

Here, Gerry Morrow discusses whether we will ever see AI fully replicate autonomous decision making and what the future role of AI in diagnostic medicine is.
medical cannabis products

Five-year license issued to “Pharma Essenza Cannabis SA” and “PENTE SA”

A five-year license has been issued to two companies allowing the cultivation and processing of medical cannabis products.
next generation cancer immunotherapy

Nano DDS technology contributes to next-generation cancer immunotherapy

Dr Takashi Nakamura from Hokkaido University challenges the potential of nano-tech based drug delivery system (Nano DDS) in the development of next-generation cancer immunotherapy.
Greenlight Medicines

GreenLight Medicines – novel plant-based medicines

GreenLight Medicines brings novel plant-based medicines to market to provide relief from serious conditions and greatly improve quality of life
Napp Pharmaceuticals Limited

Napp Pharmaceuticals Limited

Napp Pharmaceuticals Limited is a UK pharmaceutical company established in the 1920’s and based in the heart of the Cambridge science community
skills shortages

Addressing skills shortages critical to the future of UK science

The UK must address the increasing number of science skills shortages to maintain its world-leading position for medicines and vaccines research and development, says the Association of the British Pharmaceutical Industry (ABPI).
young men with anxiety, mental health

Young men with anxiety in need of more support

Research reveals that 70% of young men with anxiety report that their work performance and relationships are affected, yet well over half of them are still not seeking help.
personalised nanomedicine

Cutting-edge technology synergy in the personalised nanomedicine space: Focus on pharmaceutical nanomanufacturing

Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group explains cutting-edge technology synergy in the personalised nanomedicine space, with a special focus on pharmaceutical nanomanufacturing
medicine

From molecule to medicine

A report this week from the Office of Health Economics (OHE) shows the amazing impact medicines have had on the NHS and more widely
Chemistry in the UK

Chemistry in the UK today

Open Access Government explores the exciting world of chemistry in the UK today, including heterocycles in pharmaceuticals and the importance of inspiring the next generation to work in the field
mental health care

Mental health care and the pharmaceutical industry

Marcin Rodzinka, Project Coordinator at Mental Health Europe explains how transparency between the pharma industry and health professionals can influence the quality of mental health care in Europe today
Professional development courses

Medical and pharmaceutical statistics research: Professional development courses

Prof Thomas Jaki from the Medical and Pharmaceutical Statistics Research Unit at Lancaster University provides an overview of the professional development courses offered at the unit
pharmaceutical sector

The impact of Brexit on the pharmaceutical sector

Life Sciences sector responds to the Business, Energy and Industrial Strategy (BEIS) Committee report on the impact of Brexit on the pharmaceutical sector
new medicines

Pharma R&D productivity: Discovering new medicines

CEO of Medicines Discovery Catapult, Chris Molloy provides a compelling analysis of pharma R&D productivity and the discovery of new medicines and the role that the SME sector can play in this
brexit speech

Pharma industry responds to the Prime Minister’s latest Brexit speech

The Association of the British Pharmaceutical Industry (ABPI) – representing global pharmaceutical businesses in the UK including GSK, AstraZeneca, Pfizer and Roche – has responded to Brexit speech by Prime Minister Theresa May
Acute myeloid leukaemia

Acute myeloid leukaemia (AML) and cytarabine pharmacogenomics

Professor Jatinder Lamba from the Department of Pharmacotherapy and Translational Research gives an in-depth perspective on acute myeloid leukaemia (AML) and cytarabine pharmacogenomics Acute myeloid leukaemia (AML) is the cancer of the myeloid precursor stem cells character­ised by the appearance of immature, abnormal myeloid cells in bone marrow and other...
clinical pharmacy

From Rwanda into the clinical pharmacy in the Palatinate

As part of their partnership, Rhineland-Palatinate region of Germany and Rwanda foster the exchange of knowledge in hospital management, medical professions and psychiatric care by funding mutual visits of their local experts as this profile reveals In the course of this exchange, two young scholarship holders visited Pfalzklinikum, service provider...
Heterocyclic

The changing face of Heterocyclic Chemistry in the pharmaceutical industry

Professor of Organic Chemistry at University of York and Chairman of the Royal Society of Chemistry’s Heterocyclic and Synthesis Group, Peter O’Brien explores the role of heterocycles in the pharmaceutical industry In 2017, the Royal Society of Chemistry’s Heterocyclic and Synthesis Group celebrated its 50th anniversary. It thus appears timely...
early drug development

IDEAS: improving design, evaluation and analysis of early drug development studies

Prof Thomas Jaki from the Medical and Pharmaceutical Statistics Research Unit at Lancaster University explores a novel approach to Ph.D. training for those in the pharmaceutical industry
ministry of health

The future of the Danish Ministry of Health

Jonathan Miles from Open Access Government explored the work the Danish Ministry of Health does to improve health policy across the country The Danish Ministry of Health was officially established in June 2015 and is responsible for all healthcare policies in Denmark. Once an independent ministry when first launched in...

Follow Open Access Government